Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/07/2023 | Vigil Neuroscience, Inc. | | Grant | Stock Option Grant (Right to Buy) | 13.9k | $10.00 | $139.3k | | 06/07/2023 |
06/06/2023 | AVROBIO, Inc. | AVRO | Grant | Stock Option (Right to Buy) | 17.6k | $1.09 | $19.2k | | 06/06/2023 |
01/12/2023 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 77.1k | $30.29 | $2.3M | See footnote | 01/11/2023 |
01/12/2023 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 21.6k | $30.29 | $654k | See footnote | 01/11/2023 |
01/11/2023 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 21.7k | $29.96 | $649.6k | See footnote | 01/11/2023 |
01/11/2023 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 6.1k | $29.96 | $181.9k | See footnote | 01/11/2023 |
12/15/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 2.6k | $30.00 | $76.8k | See footnote | 12/14/2022 |
12/15/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 717 | $30.00 | $21.5k | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 112.8k | $30.28 | $3.4M | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 101.2k | $31.44 | $3.2M | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 54.7k | $32.33 | $1.8M | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 14k | $33.34 | $466.7k | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 13.3k | $34.02 | $453.7k | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 31.6k | $30.28 | $956.4k | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 28.3k | $31.44 | $890.7k | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 15.3k | $32.33 | $495.4k | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 3.9k | $33.34 | $130.7k | See footnote | 12/14/2022 |
12/14/2022 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 3.7k | $34.02 | $127k | See footnote | 12/14/2022 |
06/28/2022 | Magenta Therapeutics, Inc. | MGTA | Grant | Stock Option (Right to Buy) | 20k | $1.21 | $24.2k | | 06/28/2022 |
06/15/2022 | Kymera Therapeutics, Inc. | | Grant | Stock Option (Right to Buy) | 12k | $14.18 | $170.2k | | 06/15/2022 |
06/09/2022 | Vigil Neuroscience, Inc. | | Grant | Stock Option Grant (Right to Buy) | 12.2k | $3.10 | $37.7k | | 06/09/2022 |
06/08/2022 | AVROBIO, Inc. | AVRO | Grant | Stock Option (Right to Buy) | 17.5k | $1.06 | $18.5k | | 06/08/2022 |
03/01/2022 | Vigil Neuroscience, Inc. | | Grant | Stock Option Grant (Right to Buy) | 7.6k | $16.13 | $122.2k | | 03/01/2022 |
01/11/2022 | Vigil Neuroscience, Inc. | | Conversion | Common Stock | 2.8M | $0.00 | $0 | By Atlas Venture Fund XII, L.P. | 01/11/2022 |
01/11/2022 | Vigil Neuroscience, Inc. | | Conversion | Common Stock | 1M | $0.00 | $0 | By Atlas Venture Opportunity Fund I, L.P. | 01/11/2022 |
01/11/2022 | Vigil Neuroscience, Inc. | | Purchase | Common Stock | 535k | $14.00 | $7.5M | By Atlas Venture Fund XII, L.P. | 01/11/2022 |
01/11/2022 | Vigil Neuroscience, Inc. | | Conversion | Series A Preferred Stock | 7.9M | $0.00 | $0 | By Atlas Venture Fund XII, L.P. | 01/11/2022 |
01/11/2022 | Vigil Neuroscience, Inc. | | Conversion | Series B Preferred Stock | 2.9M | $0.00 | $0 | By Atlas Venture Opportunity Fund I, L.P. | 01/11/2022 |
08/11/2021 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 242.1k | $61.00 | $14.8M | See footnote | 08/11/2021 |
06/16/2021 | Kymera Therapeutics, Inc. | | Grant | Stock Option (Right to Buy) | 20.1k | $49.10 | $985.1k | | 06/16/2021 |
06/10/2021 | AVROBIO, Inc. | AVRO | Grant | Stock Option (Right to Buy) | 17.4k | $9.63 | $167.9k | | 06/10/2021 |
06/01/2021 | Magenta Therapeutics, Inc. | MGTA | Grant | Stock Option (Right to Buy) | 18.2k | $12.91 | $234.8k | | 06/01/2021 |
03/12/2021 | Kymera Therapeutics, Inc. | | Sale | Common Stock | 229.4k | $56.50 | $13M | See footnote | 03/12/2021 |
08/25/2020 | Kymera Therapeutics, Inc. | | Conversion | Series B Convertible Preferred Stock | 1.5M | $0.00 | $0 | See Footnote | 08/25/2020 |
08/25/2020 | Kymera Therapeutics, Inc. | | Conversion | Series C Convertible Preferred Stock | 1.8M | $0.00 | $0 | See Footnote | 08/25/2020 |
|